We claim:

1. A chemical compound comprising first and second hsp-binding moieties which bind to the pocket of hsp90 with which ansamycin antibiotics bind, said binding moieties being connected to one another by a linker.

2. The chemical compound according to claim 1, wherein the first hsp-binding moiety is an ansamycin antibiotic.

3. The chemical compound according to claim 2, wherein the first and second hsp-binding moieties are each an ansamycin antibiotic.

4. The chemical compound of claim 3, wherein at least one of the hsp-binding moieties is geldanamycin.

5. The chemical compound of claim 4, wherein the first and second hsp-binding moieties are geldanamycin.

6. The chemical compound of claim 5, wherein the linker has a length of 4 to 7 carbons atoms.

7. The chemical compound of claim 6, wherein the linker has a length of 4 carbon atoms.

8. The chemical compound of claim 1, wherein at least one of the hsp-binding moieties is geldanamycin.

9. The chemical compound of claim 8, wherein the first and second hsp-binding moieties are geldanamycin.

10. The chemical compound of claim 9, wherein the linker has a length of 4 to 7 carbons atoms.

11. The chemical compound of claim 10, wherein the linker has a length of 4 carbon atoms.

12. A method for destruction of cells expressing a HER-family tyrosine kinase, comprising administering to the cells a chemical compound according to any of claims 1-11.

13. A method for treating cancer in a patients suffering from cancer, comprising administering to the patient a therapeutic composition comprising a chemical compound according to any of claims 1-11.

14. The method of claim 13, wherein the cancer is an HER-positive cancer.